IP Library Granted Patent US 7,687,480
Granted Patent B2
US 7,687,480 · App. 11/925,309 · Granted Mar 30, 2010

Phosphonate compounds

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,687,480
App. No.
11/925,309
Granted
Mar 30, 2010
Kind
B2
Abstract

The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.

Claims (19)

1. A compound consisting a phosphonate monoester formed by a covalent linking of tenofovir to a (C 1 -C 24 )alkylpropanediol or (C 1 -C 24 )alkoxypropan-1-ol, or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein tenofovir is covalently linked to hexadecyloxypropan-1-ol.

3. The compound of claim 1 , wherein the compound has the structure:

or a pharmaceutically acceptable salt thereof.

4. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

5. A method for the treatment of a viral disease selected from human immunodeficiency virus, influenza, herpes simplex virus, human herpes virus, cytomegalovirus, hepatitis B and C virus, Epstein-Barr virus, varicella zoster virus, orthopox virus, ebola virus and papilloma virus comprising administering an effective amount of a compound optionally in a pharmaceutically acceptable carrier, wherein the compound comprises a phosphonate ester formed by a covalent linking of tenofovir to an alkylpropanediol or alkoxyalkanol, or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 , wherein tenofovir is covalently linked to hexadecyloxypropan-1-ol.

7. The method of claim 5 wherein the virus is an orthopox virus selected from the group consisting of variola major and minor, vaccinia, smallpox, cowpox, camelpox and monkeypox.

8. The method of claim 5 , wherein the virus is human immunodeficiency virus.

9. The method of claim 5 , wherein the virus is influenza.

10. The method of claim 5 , wherein the virus is herpes.

11. The method of claim 5 , wherein the virus is cytomegalovirus.

12. The method of claim 5 , wherein the virus is hepatitis B.

13. The method of claim 5 , wherein the virus is hepatitis C.

14. The method of claim 5 , wherein the virus is Epstein-Barr virus.

15. The method of claim 5 , wherein the virus is varicella zoster virus.

16. The method of claim 5 , wherein the virus is papilloma.

17. The method of claim 5 , wherein said compound has the structure:

or a pharmaceutically acceptable salt thereof.

Assignments (3)
CONFIRMATORY LICENSE Recorded Dec 13, 2018
From: UNIVERSITY OF CALIFORNIA, SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 049014/0590 →
CONFIRMATORY LICENSE Recorded Aug 6, 2008
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021344/0503 →
CONFIRMATORY LICENSE Recorded Aug 6, 2008
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021344/0559 →
Continuity (8)
Continuation 1171560400 · Mar 7, 2007
Continuation 1150629200 · Aug 17, 2006
Continuation 1110088200 · Apr 6, 2005
Continuation 1075934500 · Jan 15, 2004
Continuation 1014837400
Provisional Application 6020571900 · May 19, 2000
Provisional Application 6016881300 · Dec 3, 1999
Related Publication 20080103115A1 · May 1, 2008